Of the targets, ADRB2, CASP1, CCR5, CSF1R, MERTK, MMP2, and P2RX7 were significantly upregulated, and CDK5, CHRNB2, GRIN2B, GSK3B, and MAPK10 were significantly downregulated in AD patients compared to controls. This evidence concerns the gene MERTK and Alzheimer disease.